Breaking News Instant updates and real-time market news.

PDCO

Patterson Companies

$22.32

0.51 (2.34%)

, XEC

Cimarex Energy

$90.63

0.72 (0.80%)

09:55
06/19/18
06/19
09:55
06/19/18
09:55

Early notable gainers among liquid option names on June 19th

Notable gainers among liquid option names this morning include Patterson Companies (PDCO) $22.29 +0.47, Cimarex Energy (XEC) $91.70 +1.78, CVS Health (CVS) $69.01 +1.28, Mallinckrodt (MNK) $19.63 +0.34, and Colgate Palmolive (CL) $64.34 +1.04.

PDCO

Patterson Companies

$22.32

0.51 (2.34%)

XEC

Cimarex Energy

$90.63

0.72 (0.80%)

CVS

CVS Health

$68.52

0.79 (1.17%)

MNK

Mallinckrodt

$19.64

0.36 (1.87%)

CL

Colgate-Palmolive

$64.10

0.8 (1.26%)

  • 21

    Jun

  • 22

    Aug

PDCO Patterson Companies
$22.32

0.51 (2.34%)

03/08/18
LEHM
03/08/18
INITIATION
Target $23
LEHM
Underweight
Patterson Companies initiated with an Underweight at Barclays
Barclays analyst Steve Valiquette started Patterson Companies with an Underweight rating and $23 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
04/04/18
UPGRADE
Target $80

Outperform
Henry Schein upgraded to Outperform at Leerink
As previously reported, Leerink analyst David Larsen upgraded Henry Schein (HSIC) to Outperform from Market Perform as he believes investor concerns around Amazon (AMZN), the FTC complaint, and Patterson Companies' (PDCO) recent Q3 results are overdone. Based on a recent MEDACorp survey, the analyst believes that Henry Schein ranks #1 in overall quality of service as considered by dental practices, vet offices, and physician groups. Larsen also raised his price target on Henry Schein shares to $80 from $75.
04/06/18
CHLM
04/06/18
UPGRADE
Target $28
CHLM
Buy
Patterson Companies upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Kevin Ellich upgraded Patterson Companies to Buy from Hold and raised his price target on the stock to $28 from $23, stating that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. He also sees limited downside from the current valuation and finds the 4.7% dividend yield attractive.
XEC Cimarex Energy
$90.63

0.72 (0.80%)

05/25/18
STFL
05/25/18
NO CHANGE
Target $180
STFL
Buy
Cimarex Energy price target raised to $180 after Ward County sale at Stifel
Stifel analyst Michael Scialla said he views Cimarex Energy's Ward County divestiture favorably as the implied acreage price exceeded his expectations and the deal improves "an already stout balance sheet." Scialla raised his price target on Cimarex to $180 from $175 following the deal announcement and keeps a Buy rating on the shares.
06/19/18
COWN
06/19/18
NO CHANGE
Target $130
COWN
Outperform
Cimarex Energy second half ramp fears overdone, says Cowen
Cowen analyst Charles Robertson said investor fears about the second half ramp at Cimarex Energy are overdone since the company has the firm capacity to achieve its 2018-2019 production growth and the company maintains a very strong balance sheet. Robertson reiterated his Outperform rating and raised his price target to $130 from $115 on Cimarex Energy shares.
06/11/18
JEFF
06/11/18
NO CHANGE
JEFF
Jefferies upgrades Cimarex to Buy, downgrades Oasis to Hold
Jefferies analyst Mark Lear upgraded Cimarex Energy (XEC) to Buy from Hold and raised his price target for the shares to $107 from $98. The analyst also downgraded Oasis Petroleum (OAS) to Hold from Buy with an unchanged price target of $14. Infrastructure constraints and wider regional basis have raised growth concerns across the Permian and driven stocks to "irrational valuations," Lear tells investors in a research note. Jefferies also raised its per-barrel Brent price forecast to $77 from $64 in 2018; to $75 from $60 in 2019; and to $70 from $65 in 2020. He notes shares of Cimarex now trade at "more than half a turn discount" to the group on consensus 2018 and 2020 EBITDA. Lear believes Cimarex's recent moves to address gas flow assurance in tandem with strategic partnerships in the Permian "provide some level of relative safety on the company's ability to maintain capital guidance." The analyst cites valuation for his downgrade of Cimarex following the stock's outperformance year-to-date.
06/11/18
JEFF
06/11/18
UPGRADE
Target $107
JEFF
Buy
Cimarex Energy upgraded to Buy from Hold at Jefferies
Jefferies analyst Mark Lear upgraded Cimarex Energy to Buy and raised his price target for the shares to $107 from $98.
CVS CVS Health
$68.52

0.79 (1.17%)

06/19/18
BOFA
06/19/18
NO CHANGE
BOFA
CVS Health added to US 1 List, Schlumberger removed at BofA/Merrill
06/13/18
LEER
06/13/18
NO CHANGE
LEER
AT&T, Time Warner approval positive for PBM-MDCO deals, says Leerink
Leerink analyst Ana Gupte says that the highly anticipated AT&T (T)-Time Warner (TWX) court decision is in favor of the companies and against the DoJ, "meaningfully increasing" the probability that the two vertical mega-mergers will close, namely Aetna (AET) and Express Scripts (ESRX), and CVS (CVS) and Cigna (CI).
06/13/18
DBAB
06/13/18
NO CHANGE
DBAB
CVS, Aetna deal on track to close in second half, says Deutsche Bank
After AT&T (T) won approval to acquire Time Warner (TWX), Deutsche Bank analyst Glen Santangelo continues to believe that CVS Health's (CVS) acquisition of Aetna (AET) is on track to close in the second half of 2018. He expects the favorable Time Warner ruling to further reduce the market spreads in both CVS, Aetna and Cigna (CI), Express Scripts (ESRX) from current levels. Shares of CVS represent a "compelling investment opportunity" at current valuation levels regardless of the regulatory outcome of the deal, Santangelo tells investors in a research note. He believes Cigna's acquisition of Express Scripts is also likely to close.
06/13/18
OPCO
06/13/18
NO CHANGE
OPCO
AT&T, Time Warner merger approval favorable for big healthcare deals, says Oppenheimer
Oppenheimer analyst Mohan Naidu notes that a federal judge approved AT&T's (T) purchase of Time Warner (TWX), without conditions, in a decision on a case brought by the DoJ in November, on insufficient proof of consumer or competitive harm, in what was widely considered a vertical merger. The closely watched trial was seen as a precedent case for CVS (CVS)-Aetna (AET) and Cigna (CI)-Express Scripts (ESRX), two vertical mergers in healthcare also currently under review by DoJ, he contends.
MNK Mallinckrodt
$19.64

0.36 (1.87%)

05/04/18
WELS
05/04/18
NO CHANGE
Target $15
WELS
Market Perform
Mallinckrodt price target lowered to $15 on stannsoporfin news at Wells Fargo
Wells Fargo analyst David Maris lowered his price target on Mallinckrodt to $15 from $17.50 after deciding to take stannsoporfin sales out of his model following the joint meeting of the FDA's GI Drugs Advisory Committee and Pediatric Advisory Committee, during which the panel overwhelmingly voted against the approval of stannsoporfin. He spoke with Mallinckrodt after the AdComm and the company said it is "disappointed" with the result and that a path forward for stannsoporfin will be evaluated to see if it makes sense to continue development, Maris noted. He maintains a Market Perform rating on Mallinckrodt shares.
05/04/18
MZHO
05/04/18
NO CHANGE
Target $13
MZHO
Neutral
Mallinckrodt likely to terminate jaundice program, says Mizuho
Mizuho analyst Irina Koffler expects Mallinckrodt to terminate its drug for severe jaundice after an FDA advisory panel recommended against approval. Termination could result in 15c-20c in earnings upside in 2018, Koffler tells investors in a research note. She views the news as a pipeline setback and keeps a Neutral rating on Mallinckrodt.
06/19/18
RHCO
06/19/18
NO CHANGE
Target $21
RHCO
Hold
Mallinckrodt price target raised to $21 from $14 at SunTrust
SunTrust analyst John Boris raised his price target on Mallinckrodt to $21 after the company reported positive Acthar interim data from its OL RA trial at Eular 2018. Boris says the efficacy data will help the company in its payer negotiations to stabilize Accthar and helps to de-risk his forecast for Acthar sales at $1.09B this year and $1.04B next year. The analyst keeps his Hold rating on Mallinckrodt, citing unpredictable long term growth path and declining Acthar volumes due to reimbursement issues.
05/09/18
LEHM
05/09/18
NO CHANGE
Target $12
LEHM
Underweight
Mallinckrodt price target lowered to $12 from $20 at Barclays
Barclays analyst Douglas Tsao lowered his price target for Mallinckrodt to $12 and keeps an Underweight rating on the shares. While Stannsaporfin was not expected to be a big product commercially, its failure to get the FDA panel vote raises questions on Mallinckrodt's "R&D acumen," Tsao tells investors in a research note. Further, the analyst believes uncertainty on Acthar is likely to persist.
CL Colgate-Palmolive
$64.10

0.8 (1.26%)

05/24/18
BERN
05/24/18
NO CHANGE
Target $72
BERN
Market Perform
Colgate-Palmolive could be target for activists, says Bernstein
Bernstein analyst Ali Dibadj says his sum-of-the-parts analysis suggests Colgate-Palmolive's businesses, even beyond Oral Care, could be attractive to other owners, with areas for improvement more notably across Home Care and Pet Food. The analyst believes the company's stock could be a target for activists given its more realistic current valuation, with various levers at play to drive fundamental improvement and earnings growth. Dibadj reiterates a Market Perform rating and $72 price target on the shares.
05/25/18
ARGS
05/25/18
UPGRADE
ARGS
Buy
Colgate-Palmolive upgraded to Buy from Hold at Argus
05/25/18
05/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he believes PayPal is in the early stages of transforming from an online checkout company to a global payments platform. 2. Novartis (NVS) upgraded to Neutral from Underperform at Credit Suisse. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at Argus analyst John Eade saying the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. 4. Best Inc. (BSTI) upgraded to Buy from Neutral at Citi. 5. Loma Negra (LOMA) upgraded to Outperform from Market Perform at Itau BBA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
05/25/18
ARGS
05/25/18
UPGRADE
Target $72
ARGS
Buy
Colgate-Palmolive upgraded to Buy at Argus on valuation
As reported earlier, Argus analyst John Eade upgraded Colgate-Palmolive to Buy from Hold with a price target of $72. The analyst says the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. Eade further states that his $72 price target implies a multiple of 21-times forward earnings, which is still below the midpoint of the company's historical range.

TODAY'S FREE FLY STORIES

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

SBLK

Star Bulk Carriers

$8.21

0.13 (1.61%)

17:03
02/15/19
02/15
17:03
02/15/19
17:03
Hot Stocks
Star Bulk Carriers acquires 95,605 of its common shares »

Star Bulk Carriers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLI

Hollysys

$20.56

0.26 (1.28%)

17:02
02/15/19
02/15
17:02
02/15/19
17:02
Earnings
Hollysys reports Q2 adjusted EPS 73c, consensus 59c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

AKS

AK Steel

$2.98

-0.015 (-0.50%)

16:58
02/15/19
02/15
16:58
02/15/19
16:58
Syndicate
Breaking Syndicate news story on AK Steel »

AK Steel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
02/15/19
02/15
16:55
02/15/19
16:55
General news
Treasury Market Summary: i »

Treasury Market Summary:…

LPTX

Leap Therapeutics

$1.65

(0.00%)

16:53
02/15/19
02/15
16:53
02/15/19
16:53
Hot Stocks
Valence Helix Investments discloses 10.99% stake in Leap Therapeutics »

Valence Helix disclosed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$23.25

-0.24 (-1.02%)

16:52
02/15/19
02/15
16:52
02/15/19
16:52
Hot Stocks
Mid Penn Bancorp seeks approval to relocate Allentown Boulevard branch »

Mid Penn Bank, subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$423.79

8.54 (2.06%)

, AMGN

Amgen

$188.31

1.6 (0.86%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
Regeneron says EPO revokes Immunex's European patent No. 2,990,420 »

Regeneron…

REGN

Regeneron

$423.79

8.54 (2.06%)

AMGN

Amgen

$188.31

1.6 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    Apr

  • 13

    May

UPS

UPS

$110.89

-0.91 (-0.81%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
UPS CFO sells 9.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DAL

Delta Air Lines

$51.09

0.58 (1.15%)

16:43
02/15/19
02/15
16:43
02/15/19
16:43
Syndicate
Breaking Syndicate news story on Delta Air Lines »

Delta Air Lines files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.89

-0.91 (-0.81%)

16:42
02/15/19
02/15
16:42
02/15/19
16:42
Hot Stocks
UPS raises quarterly dividend to 96c per share from 91c »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.